The FDA has approved Ocrevus (ocrelizumab) for the treatment of adults with primary progressive MS and with relapsing MS.
List cost is $65,000 per year so access will depend on individual insurance plans.
For people who qualify, Genentech plans to offer patient assistance programs through Genentech Access Solutions: (866) 4ACCESS/(866) 422-2377 or http://www.Genentech-Access.com.
- Ocrevus Information for Consumers
- Ocrevus Information for Healthcare Professionals (includes dosage details)
- Side Effects of Ocrevus (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 5 Apr 2016 • 3 answers
Posted 2 Apr 2017 • 0 answers
Posted 23 Jun 2017 • 0 answers
Posted 5 Jul 2017 • 1 answerFAQ by Drugs.com
Posted 28 Jan 2018 • 0 answers